Auch das nächste Votum steht auf "Halten":
Zacks Investment Research Analysts Give Cytokinetics, Inc. (NASDAQ: CYTK) a “Neutral” Rating
January 3rd, 2011 • Related • Filed Under • by ACN Staff
Filed Under: Stock Market News
Zacks Investment Research research analysts reiterated a “neutral” rating for shares of Cytokinetics, Inc. (NASDAQ: CYTK) in a research note issued to investors on Tuesday.
Cytokinetics, Inc. (NASDAQ: CYTK)’s stock opened at 2.09 on Monday. Cytokinetics, Inc. has a 52 week range of $2.01 to $3.78. The stock’s 50-day moving average is $2.25 and its 200-day moving average is $2.42. Analysts predict on average that Cytokinetics, Inc. will post $-0.20 earnings per share next quarter. The company has a market cap of $137.7 million and a P/E (price-to-earnings ratio) of N/A.
|aus der Diskussion:||ALS - Biotech machts möglich?|
|Autor (Datum des Eintrages):||Karl79 (03.01.11 18:49:08)|
|Beitrag:||7 von 9 (ID:40791463)|
|Alle Angaben ohne Gewähr © wallstreet:online|